KUR.F Kura Oncology Inc

Healthcare Biotechnology Frankfurt Exchange
6.60 EUR
Close of Nov 13, 2026
5.98 11.80
Market cap
EUR 606M
P/E
-
P/B
40.57x
ROE
-1,572.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is KUR.F undervalued?

Graham number

The Graham number of Kura Oncology Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Kura Oncology Inc fundamental analysis

No fundamental analysis for Kura Oncology Inc yet.

Kura Oncology Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibi…

Full company profile